Palvella Therapeutics (PVLA) Surges On Positive Phase 3 QTORIN SELVA Data

Palvella Therapeutics stock is trading near recent highs. Where are PVLA shares going?Phase 3 SELVA Trial SucceedsThe trial in 49 patients aged six and older met its primary endpoint on the Microcystic Lymphatic Malformation Investigator Global Assessment, with a mean improvement of over two points and gains across all key secondary measures. Most participants were rated much or very improved, and nearly all eligible patients chose to roll into an extension study.First Potential Therapy For MicrocysticQTORI ...